Protagonist Therapeutics, Inc.

NASDAQ:PTGX

41.49 (USD) • At close December 20, 2024
Bedrijfsnaam Protagonist Therapeutics, Inc.
Symbool PTGX
Munteenheid USD
Prijs 41.49
Beurswaarde 2,472,721,020
Dividendpercentage 0%
52-weken bereik 21.43 - 48.89
Industrie Biotechnology
Sector Healthcare
CEO Dr. Dinesh V. Patel Ph.D.
Website https://www.protagonist-inc.com

An error occurred while fetching data.

Over Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis,

Vergelijkbare Aandelen

Sight Sciences, Inc. logo

Sight Sciences, Inc.

SGHT

3.57 USD

Akoya Biosciences, Inc. logo

Akoya Biosciences, Inc.

AKYA

2.49 USD

ADMA Biologics, Inc. logo

ADMA Biologics, Inc.

ADMA

17.4 USD

AxoGen, Inc. logo

AxoGen, Inc.

AXGN

15.64 USD

Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc.

TARS

52.91 USD

OrganiGram Holdings Inc. logo

OrganiGram Holdings Inc.

OGI

1.56 USD

Repare Therapeutics Inc. logo

Repare Therapeutics Inc.

RPTX

1.32 USD

Incannex Healthcare Limited logo

Incannex Healthcare Limited

IXHL

0.84 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)